BREAKWATER Study: Encorafenib, Cetuximab, and Chemotherapy for BRAF-Mutant mCRC

Christina Wu, MB, BCh, MD, shares data from the phase 3 BREAKWATER trial, which assesses first-line targeted treatment strategies for patients with BRAF V600E-mutant metastatic colorectal cancer.